Skip to main content
SpringerLink
Log in

Insulin Resistance and Dyslipidemia

  • Chapter
The Metabolic Syndrome

Part of the book series: Contemporary Endocrinology ((COE))

  • 1551 Accesses

Abstract

During the past two decades, there has been an increasing recognition of the significance of a clustering of cardiovascular disease (CVD)risk factors, leading expert panels to formally link them as the metabolic syndrome (1,2). Although there has been controversy regarding the criteria to be used in defining the metabolic syndrome, and the utility of the term itself (3–5), it is clear that the featured components of central obesity, hypertension, dyslipidemia, and abnormal glucose metabolism commonly coexist in individuals at high risk for CVD and type 2 diabetes mellitus (T2DM). It has been widely recognized that insulin resistance (IR) plays a central, unifying role in the pathophysiology of this syndrome. In this chapter, we will focus on the associations between IR and the dyslipidemia characterized by high plasma triglyceride (TG) levels, reduced plasma high-density lipoprotein (HDL) cholesterol concentrations, and abnormalities in low-density lipoprotein (LDL) composition and size in the face of relatively normal plasma LDL cholesterol (LDL-C) levels.

Supported by NIH grants from NHLBI: ROl HL69190, ROl HL55638, ROl HL73030, T32 HL07343

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional Report of a WHO Consultation. Diab Med 1998; 15:539–553.

    Article  CAS  Google Scholar 

  2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285(19):2486–2497.

    Google Scholar 

  3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415–1428.

    Article  CAS  PubMed  Google Scholar 

  4. Kahn R, Buse J, Ferrannini E, Stern M, merican Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289–2304.

    Article  PubMed  Google Scholar 

  5. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: A new worldwide definition. Lancet 2005; 366:1059–1062.

    Article  PubMed  Google Scholar 

  6. Albrink MJ, Man EB. Serum triglycerides in health and diabetes. Diabetes 1958; 7:194–201.

    CAS  PubMed  Google Scholar 

  7. Lopes-Virella MF, Stone PG, Colwell JA. Serum high density lipoprotein in diabetic patients. Diabetologia 1977; 13:285–291.

    Article  CAS  PubMed  Google Scholar 

  8. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetes states. Diabetes Care 1991; 14:839–855.

    Article  CAS  PubMed  Google Scholar 

  9. Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 1967; 46:1756–1767.

    CAS  PubMed  Google Scholar 

  10. Reaven GM, Chen Y-D. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 1988; 4:639–652.

    Article  CAS  PubMed  Google Scholar 

  11. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005; 36:232–240.

    Article  CAS  PubMed  Google Scholar 

  12. Austin MA, King MD, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495–506.

    CAS  PubMed  Google Scholar 

  13. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterowovich PO. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Int Med 1982; 97:33–839.

    Google Scholar 

  14. Goff DC Jr, D’ Agostino RB Jr, Haffner SM, Saad MF, Wagenknecht LE. Lipoprotein concentrations and carotid atherosclerosis by diabetes status: Results from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2000; 23:1006–1011.

    Article  CAS  PubMed  Google Scholar 

  15. Goff DC Jr, D’ Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations: Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005; 54:264–270.

    Article  CAS  PubMed  Google Scholar 

  16. Howard BV, Mayer-Davis EJ, Goff D et al. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: The Insulin Resistance Atherosclerosis Study. Metabolism 1998; 47:1174–1179.

    Article  CAS  PubMed  Google Scholar 

  17. Festa A, Williams K, Hanley AJ et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005; 111:3465–472.

    Article  PubMed  Google Scholar 

  18. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893–2898.

    Article  CAS  PubMed  Google Scholar 

  19. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: An atherogenic disorder common in patients with diabetes. Am J Cardiol 2001; 88:9H–15H.

    Article  CAS  PubMed  Google Scholar 

  20. Annuzzi G, De Natale C, Iovine C et al. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterio Thromb Vasc Biol 2004; 24:2397.

    Article  CAS  Google Scholar 

  21. Ginsberg HN. Association of postprandial triglyceride and Retinyl Palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle aged men and women. Arterio Thromb Vasc Biol 1995; 15:1829–1838.

    CAS  Google Scholar 

  22. Sharret AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. Arterio Thromb Vasc Biol 1995; 15:2122–2129.

    Google Scholar 

  23. Ginsberg HN. New perspectives on atherogenesis: Role of abnormal triglyceride rich lipoprotein metabolism. Circulation 2002; 106:2137–2142.

    Article  PubMed  Google Scholar 

  24. Ginsberg HN. Hypertriglyceridemia: New insights and new approaches to pharmacologic therapy. Am J Cardiolz 2001; 87:1174–1180.

    Article  CAS  Google Scholar 

  25. Krauss RM, Siri PW. Metabolic abnormalities: Triglyceride and low-density lipoprotein. Endocrinol Metab Clinic NA 2004; 33:405–415.

    Article  CAS  Google Scholar 

  26. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: The assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002; 277:7377–17380.

    Article  Google Scholar 

  27. Yao Z, Tran K, McLeod RS. Intracellular degradation of newly synthesized apolipoprotein B. J Lipid Res 1997; 38(10):1937–1953.

    CAS  PubMed  Google Scholar 

  28. Fisher EA, Pan M, Chen X et al. The triple threat to nascent apolipoprotein B: Evidence for multiple, distinct degradative pathways. J Biol Chem 2001; 276:27855–27863.

    Article  CAS  PubMed  Google Scholar 

  29. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1994; 1215:9–32.

    CAS  PubMed  Google Scholar 

  30. Otarod JK, Goldberg IJ. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep 2004; 6:335–342.

    Article  PubMed  Google Scholar 

  31. Ginsberg HN, Le N-A, Goldberg IJ et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein C-III and A-I: Evidence that apolipoprotein C-III inhibits lipoprotein lipase in vivo. J Clin Invest 1986; 78:1287–1295.

    Article  CAS  PubMed  Google Scholar 

  32. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001; 12:297–304.

    Article  CAS  PubMed  Google Scholar 

  33. Pennacchio LA, Olivier M, Hubacek JA et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294:169–172.

    Article  CAS  PubMed  Google Scholar 

  34. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: Synergistic actors in triglyceride metabolism? Curr Opin Lipidol 2004; 15:239–246.

    Article  PubMed  Google Scholar 

  35. Merkel M, Loeffler B, Kluger M et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280:21553–21560.

    Article  CAS  PubMed  Google Scholar 

  36. Goldberg IJ. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherosclerosis. J Lipid Res 1996; 37:693–707.

    CAS  PubMed  Google Scholar 

  37. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997; 38(11):2173–2192.

    CAS  PubMed  Google Scholar 

  38. Windler E, Chao Y, Havel RJ. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem 1980; 255:5475–5480.

    CAS  PubMed  Google Scholar 

  39. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998; 18:297–330.

    Article  CAS  PubMed  Google Scholar 

  40. Dram JF, Heinecke JW. ATP-binding cassette transporter AI: A cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005; 85:1343–1372.

    Article  Google Scholar 

  41. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters Gl and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101:9774–9779.

    Article  CAS  PubMed  Google Scholar 

  42. Hussain MM, Kedees MH, Singh K, Athar H, Jamali NZ. Signposts in the assembly of chylomicrons. Frontiers Biosci 2001; 6:d320–d331.

    Article  CAS  Google Scholar 

  43. Yu Y, Ginsberg HN. Adipocyte signaling and lipid homeostasis: Sequelae of insulin-resistant adipose tissue. Circ Res 2005; 96:1042–1052.

    Article  CAS  PubMed  Google Scholar 

  44. Zechner R, Strauss JG, Haemmerle G, Lass A, Zimmermann R. Lipolysis: Pathway under construction. Curr Op LipidoI 2005; 16:333–340.

    Article  CAS  Google Scholar 

  45. Kissebah AH, Alfarsi S, Adams PW, Seed M, Folkard J, Wynn V. Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglycerideaemia. Atherosclerosis 1976; 24:199–218.

    Article  CAS  PubMed  Google Scholar 

  46. Ginsberg HN. Very low density lipoprotein metabolism in diabetes mellitus. Diab/Metab Rev 1987; 3:571–589.

    Article  CAS  Google Scholar 

  47. Zhang Y-L, Hernandez-Ono A, Ko C, Yasunaga K, Huang L-S, Ginsberg HN. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids 1: Differential effects of delivering fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 2004; 279:19362–19374.

    Article  CAS  PubMed  Google Scholar 

  48. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125–1131.

    CAS  PubMed  Google Scholar 

  49. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5-phosphate mediates glucoseinduced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. PNAS 2003; 100:5107–5112.

    Article  CAS  PubMed  Google Scholar 

  50. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. PNAS 2004; 101:11245–11250.

    Article  CAS  PubMed  Google Scholar 

  51. Gavrilova O, Haluzik M, Matsusue K et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003; 278:34268–34276.

    Article  CAS  PubMed  Google Scholar 

  52. Herzig S, Hedrick S, Morantte I, Koo S-H, Galimi F, Montminy M. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-. Nature 2003; 426:190–193.

    Article  CAS  PubMed  Google Scholar 

  53. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 2004; 89:3949–3955.

    Article  CAS  PubMed  Google Scholar 

  54. Altomonte J, Cong L, Harbaran S et al. Foxol mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004; 114:1493–1503.

    CAS  PubMed  Google Scholar 

  55. Nowak M, Helleboid-Champman A, Jakel H et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: Role of upstream stimulatory factor. Mol Cell Biol 2005; 25:1537–1548.

    Article  CAS  PubMed  Google Scholar 

  56. Ebara T, Conde K, Kako Y et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000; 105(12):1807–1818.

    Article  CAS  PubMed  Google Scholar 

  57. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very-low-density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982; 31:217–225.

    Article  CAS  PubMed  Google Scholar 

  58. Stein O, Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 2005; 178:217–230.

    Article  CAS  PubMed  Google Scholar 

  59. Sharret AR, Heiss G, Chambless LE et al. Metabolic and lifestyle determinants of postprandial lipemia differ from those of fasting triglycerides: The Atherosclerosis Risk in Communities (ARIC) Study. Arteria Thromb Vasc Biol 2001; 21:275–281.

    Google Scholar 

  60. Despres JP. Gender difference in postprandial lipemia: Importance of visceral adipose tissue accumulation. Arteria Thromb Vasc Biol 1999.

    Google Scholar 

  61. Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: Deregulation of hepatic and intestinal lipoprotein secretion. Frontiers Biosci 2003; 8:64–476.

    Article  Google Scholar 

  62. Guo Q, Avramoglu RK, Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: Evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 2005; 54:689–697.

    Article  CAS  PubMed  Google Scholar 

  63. Brunzell JD, Hazzard WR, Porte DJ, Bierman EL. Evidence for a common saturable triglyceride removal mechanism for chylomicrons and very low density lipoprotein in man. J Clin Invest 1973; 52:1578.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Columbia University School of Medicine, New York, NY

    Tina J. Chahil MD, Gissette Reyes MD & Henry N. Ginsberg MD (Professor of Medicine)

Authors
  1. Tina J. Chahil MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gissette Reyes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry N. Ginsberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Obesity, Diabetes, and Aging Research Center, University of South Florida College of Medicine, Tampa, FL

    Barbara Caleen Hansen PhD (Professor of Internal Medicine and Pediatrics Director) (Professor of Internal Medicine and Pediatrics Director)

  2. Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA

    George A. Bray MD (Boyd Professor) (Boyd Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chahil, T.J., Reyes, G., Ginsberg, H.N. (2008). Insulin Resistance and Dyslipidemia. In: Hansen, B.C., Bray, G.A. (eds) The Metabolic Syndrome. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-116-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-116-5_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-738-9

  • Online ISBN: 978-1-60327-116-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation